リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease

野上 麻子 横浜市立大学

2022.03.25

概要

Abstract
Aim
Although liver biopsy is the gold standard for the diagnosis and staging of non-alcoholic fatty liver disease (NAFLD), repeated assessment of patients’ liver tissue conditions are impractical. We assessed the 10-year changes in liver stiffness measurements (LSM) utilizing vibration-controlled transient elastography in NAFLD patients.

Methods
From January 2006 to September 2007, LSM was carried out for 97 biopsy-proven NAFLD patients. Of these, 34 patients underwent 10-year LSM reassessments (14 of them with paired biopsies).

Results
We evaluated the changes in the fibrosis stage as estimated using LSM (FS-LSM). Over a 10-year period, 32.4% had FS-LSM progression, 50% had static disease, and 17.6% had FS-LSM improvement. From among the initially diagnosed non-alcoholic steatohepatitis patients, 18% had progressed to considerable stage 4 (cirrhosis) 10 years later. In this cohort, none of the patients who had been initially diagnosed as FS-LSM stage 0 had progressed to cirrhosis 10 years later. The changes in LSM were correlated with the change in the histological fibrosis stage, the NAFLD activity score, and the change in the sum of the steatosis, activity, and fibrosis score. Improving more than 1 body mass index (kg/m2) and having a higher initial aspartate aminotransferase, alanine aminotransferase (ALT), or ALT responder (>30% improvement or reduction to less than 40 IU/L) were factors contributing to LSM improvements (≥2 kPa).

Conclusions
Vibration-controlled transient elastography is likely to become a more clinically important tool for the long-term monitoring of NAFLD patients.

参考文献

Hasegawa S, Yoneda M, Kurita Y, Nogami A, Honda Y, Hosono K, Nakajima A.Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents.Drugs. 2021; 81: 1181-1192.

Honda Y, Ozaki A, Iwaki M, Kobayashi T, Nogami A, Kessoku T, Ogawa Y, Tomeno W,Imajo K, Yoneda M, Saito S, Nagashima Y, Nakajima A. Protective effect of SGL5213, apotent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcohlic fatty liver disease in mice. J pharmacol Sci 2021; 147: 176-183.

Iwaki M, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y,Imajo K, Yoneda M, Maeda A, Tanaka Y, Nakajima S, Ohno H, Usuda H, Kawanaka M,Kawaguchi T, Torimura T, Kage M, Hyogo H, Takahashi H, Eguchi Y, Aishima S, WadaK, Kobayashi N, Sumida Y, Saito S, Nakajima A. Gut microbiota compositionassociated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease.

J Gastroenterol Hepatol. 2021; 36: 2275-2284.

Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A,Takahashi K, Kasai Y, OzakiA, Iwaki M, Nogami A, Honda Y, Ogawa Y, Kato S, Higurashi T, Hosono K, Yoneda M,Okamoto T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Endotoxins andNon-Alcoholic Fatty Liver Disease. Front Endocrinol. 2021; 12: 770986.

Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A,Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K,Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. The Role of Leaky Gut inNonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci. 2021; 22:8161.

Nogami A, Saito S, Hasegawa H, Yoneda M, Harada K, Fujikawa H.Lymphoepithelioma-like cholangiocarcinoma with Epstein-Barr virus infection treatedby radiofrequency ablation. Clin J Gastroenterol. 2021; 14: 638-644.

Tomeno W, Imajo K, Takayanagi T, Ebisawa Y, Seita K, Takimoto T, Honda K, Kobayashi T,Nogami A, Kato T, Honda Y, Kessoku T, Ogawa Y, Kirikoshi H, Sakamoto Y, Yoneda M, SaitoS, Nakajima A. Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs, Diagnostics. 2020; 10: 912.

Yoneda M, Honda Y, Nogami A, Imajo K, Nakajima A. Advances in ultrasound elastographyfor nonalcoholic fatty liver disease. J Med Ultrason. 2020; 47: 521-533.

Yoneda M, Honda Y, Ogawa Y, Kessoku T, Kobayashi T, Imajo K, Ozaki A, Nogami A, TaguriM, Yamanaka T, Kirikoshi H, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Comparing theeffects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. BMJ Open Diabetes Res Care. 2021; 9 e001990.

Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, Kobayashi T, Nogami A,Higurashi T, Kato S, Hosono K, Saito S, Nakajima A. Risk of cardiovascular disease in patientswith fatty liver disease as defined from the metabolic dysfunction associated fatty liver diseaseor nonalcoholic fatty liver disease pont of view: a retrospective nationwide claims databasestudy in Japan. J Gastroenterol. 2021; 56: 1022-1032.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文

一発検索!

この論文の関連論文を見る